Charles River Laboratories International, Inc. — Q3 2015 Form 10-Q
Business context and period: The company provides early-stage contract research services, research models, and products and services supporting manufacturing. This unaudited report covers the three and nine months ended September 26, 2015; comparisons are to the periods ended September 27, 2014. Amounts below are in U.S. dollars.
Financial performance
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $349.5M | $327.6M | $1,009.5M | $968.1M |
| Operating income | $55.4M | $46.2M | $154.2M | $136.9M |
| Net income attributable to common shareholders | $37.4M | $32.0M | $117.4M | $99.5M |
| Diluted EPS | $0.79 | $0.68 | $2.47 | $2.11 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $185.9M | $152.3M |
- Margins: Q3 operating margin was approximately 15.9%, versus 14.1%; nine-month operating margin was approximately 15.3%, versus 14.1%. Q3 gross costs of products and services were 60.5% of revenue, down from 63.9%; SG&A was 21.8% of revenue, up from 19.7%.
- Cash and liquidity: Cash and cash equivalents were $74.0M at September 26, down from $160.0M at December 27, 2014. Current assets were $578.7M and current liabilities $314.1M. Management stated existing funds, operating cash generation, and financing access were sufficient for foreseeable operations.
- Debt: Debt was approximately $825.1M, compared with $753.8M at year-end 2014. The amended $1.3B credit facility comprises a $400M term loan and $900M revolving facility; weighted-average debt interest rate was 1.31%. The company reported compliance with covenants.
- Capital allocation: Nine-month capital expenditures were $35.0M and treasury stock purchases were $117.4M. The repurchase authorization had $69.7M remaining.
Changes versus comparable periods
- Q3 revenue rose 6.7%; nine-month revenue rose 4.3%. Foreign exchange reduced revenue by $18.2M in Q3 and $56.3M for the nine months, equivalent to 5.5% and 5.8%, respectively, of prior-period revenue.
- Discovery and Safety Assessment revenue increased 12.4% in Q3 and 16.2% year to date, supported by Safety Assessment volume, pricing and market-share gains, and acquisitions. Research Models and Services revenue declined 4.5% in Q3 and 8.0% year to date, primarily due to currency effects. Manufacturing Support increased 16.0% in Q3 and 5.0% year to date, including acquisition contributions.
- Operating income and diluted EPS increased in both comparison periods. Nine-month net income also benefited from a lower effective tax rate: 18.3% versus 26.2%, including tax-position releases and the non-taxable Sunrise bargain-purchase gain.
- Cash from operations increased to $185.9M from $152.3M. Investing cash use increased to $249.0M from $217.2M, principally reflecting acquisitions and higher capital expenditures.
Outlook, commentary and notable items
- The filing provides no specific revenue, earnings, or margin guidance. Management cited demand growth in Safety Assessment and acquisitions, while noting foreign-exchange pressure; its liquidity assessment is based on the current business plan.
- The July 2015 Celsis acquisition cost approximately $214M, including assumed debt and certain liabilities. Celsis contributed $4.9M revenue and a $3.1M operating loss after acquisition through quarter-end. Sunrise was acquired in May for approximately $9.6M; the company recorded a $9.9M bargain-purchase gain.
- Acquisition and integration costs, higher stock-based compensation, and increased corporate SG&A weighed on expenses. The nine-month effective tax rate was unusually low, partly due to a $10.4M reduction in unrecognized tax benefits and the non-taxable Sunrise gain; these items should not be assumed recurring.
- Foreign-currency translation reduced comprehensive income, and accumulated other comprehensive loss increased to $120.8M from $74.2M at year-end. A 100-basis-point rise in interest rates was estimated to increase annual pretax interest expense by approximately $13M.
- Contingencies include a government-contract billing investigation, with a $1.5M reserve and possible additional loss that cannot presently be estimated, and an IDEXX patent-infringement lawsuit for which the company could not estimate a possible loss range. The company said ordinary-course litigation was not expected to materially affect its financial condition.
- A Quebec tax-law change enacted after quarter-end was expected to affect fourth-quarter operating income and increase the effective tax rate. The filing identifies currency, interest-rate, acquisition-integration, tax, litigation, and goodwill or asset-impairment risks.
Important facts for investors to verify
- How much reported growth reflects underlying demand versus acquisitions, pricing, and foreign exchange.
- Whether segment margin improvement, especially in Discovery and Safety Assessment, is sustainable as acquisition and integration costs evolve.
- Debt levels, revolving-facility use, floating-rate exposure, and liquidity following acquisitions, repurchases, and the decline in cash.
- The repeatability of earnings given the favorable tax items and Sunrise bargain-purchase gain.
- Any updates to the IDEXX litigation, government-contract investigation, Quebec tax effects, and preliminary acquisition valuations.